Lifeward Ltd. Reports Third Quarter 2025 Financial Results

Rhea-AI Summary

Lifeward (Nasdaq: LFWD) reported Q3 2025 results on Nov 14, 2025: revenue $6.2M (Q3 2024: $6.1M), net loss $3.2M or $0.20 per share, and cash used in operations $3.8M.

Key operational progress included a record quarter of ReWalk placements for Medicare beneficiaries, a 16% year‑over‑year reduction in quarterly cash burn, a 27% decline in quarterly non‑GAAP operating loss, and CE mark approval for ReWalk 7 enabling sales in Europe (~40% of exoskeleton sales). Lifeward also secured a $3.0M loan from Oramed and reaffirmed 2025 guidance of $24–$26M revenue and $12–$14M non‑GAAP net loss.

Positive

• Record Medicare ReWalk placements in Q3 2025
• Cash burn improved by 16% YoY to $3.8M
• Non‑GAAP operating loss down 27% YoY
• CE mark for ReWalk 7 enables Europe sales (~40% of exoskeleton sales)
• $3.0M loan from Oramed provides immediate capital support

Negative

• Unrestricted cash of only $2.0M at Sept 30, 2025
• Q3 net loss of $3.2M (loss per share $0.20)
• AlterG product revenue declined 15% YoY in Q3
• Full‑year 2025 expected non‑GAAP net loss of $12–$14M

Insights

Corporate finance analyst

Revenue modestly up; operational efficiency improved but cash remains tight despite a $3.0M loan and reaffirmed 2025 guidance.

Revenue in Q3 reached $6.2 million, a 1% year-over-year increase, driven by a $3.1 million contribution from traditional products and Medicare-related sales growth. Gross margin expanded to 43.7%, aided by lower production costs after the Fremont facility closure; adjusted operating expenses fell by $1.0 million year-over-year on a non-GAAP basis.

Liquidity remains the central dependency and risk: unrestricted cash was $2.0 million as of September 30, 2025, with quarterly cash used in operations improving to $3.8 million from $4.5 million a year earlier. The company secured a $3.0 million loan agreement to bolster liquidity, but the confirmed cash level plus that facility roughly covers a short span of operating cash burn if trends persist. The business also depends on continued Medicare and Medicare Advantage reimbursements and the newly obtained CE mark for the ReWalk 7 to sustain international sales (approximately 40% of exoskeleton sales).

Concrete items to watch over the next quarter and full year include Q4 operating cash burn and ending cash balances, realization of expected revenue in the reaffirmed full-year range of $24 million to $26 million, and the projected non-GAAP net loss range of $12 million to $14 million for 2025. Also monitor quarterly Medicare placement trends following the Medicare fee schedule and initial Medicare Advantage commercial revenue to assess durability of recent Medicare-driven growth.

Record quarter of ReWalk systems placed for Medicare beneficiaries since fee schedule established 

Ongoing efficiency initiatives drive 16% year-over-year decrease in quarterly cash burn and 27% decrease in quarterly Non-GAAP operating loss

Entered into $3.0 million loan agreement with Oramed Ltd. providing additional capital support

MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd., (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced its financial results for the three months and nine months ended September 30, 2025.

Recent Corporate Highlights

• Record ReWalk: Q3 marked Lifeward’s second consecutive record quarter for Medicare beneficiary placements - the highest since Medicare formalized its fee schedule in April 2024.
• Operational Efficiency: Improved quarterly cash burn to $3.8 million, down from $4.5 million in Q3 2024, reflecting cost-structure optimization, facility consolidation, and improved reimbursement efficiency.
• Strategic Funding: Secured $3.0 million loan from Oramed Ltd. to support ongoing operations and strategic initiatives.
• Medicare Advantage Expansions: Received the first commercial revenue under a Medicare Advantage plan coverage for a ReWalk 7 Personal Exoskeleton.
• CE Mark Approval: Received CE mark for the ReWalk 7 Personal Exoskeleton, enabling commercial sales in Europe, which currently represents approximately 40% of the Company’s exoskeleton sales.

“During the third quarter of 2025, Lifeward continued to make steady progress across commercial execution, operations, and patient access,” said Mark Grant, President and Chief Executive Officer. “Since joining the company, I’ve taken a careful look at our business and implemented a focused plan to simplify how we operate, sharpen our commercial priorities, and strengthen the processes that matter most to patients, payors and providers. The gains we saw this quarter - record Medicare placements, and meaningful improvements in operating efficiency - are early signs that this work is starting to take hold. These results reflect the commitment of our teams and the growing alignment across the organization. We recognize there is more to do to complete our transformation over the coming quarters, and the momentum we are seeing gives us confidence. With CE mark approval, broader Medicare access, and a more disciplined commercial model, Lifeward is becoming a more focused, more efficient, and more patient-centered company - positioned to serve more people and create durable long-term value.”

Third Quarter 2025 Financial Results

Revenue was $6.2 million in the third quarter of 2025, compared to $6.1 million in the third quarter of 2024, an increase of $0.1 million, or approximately 1%. Compared to the second quarter of 2025, when revenue was $5.7 million, this represents an additional increase of approximately 8%. Revenue from the sale of traditional products and services, including the ReWalk Personal exoskeletons and the MyoCycle FES bike, was $3.1 million, up $0.6 million, or 24% compared to the prior-year quarter. This increase is attributable to Medicare related sales that grew year over year. Revenue from the sale of AlterG products and services was $3.1 million, compared to $3.6 million in the third quarter of 2024, a decrease of $0.5 million, or approximately 15%. This decrease primarily driven by timing factors and quarterly revenue mix sales. Gross margin was 43.7% during the third quarter of 2025, compared to 36.2% in the third quarter of 2024. On a non-GAAP basis, which excludes the amortization of purchase price allocation adjustments and stock-based compensation expense as detailed in the attached non-GAAP reconciliation table, adjusted gross margin was 43.7% in the third quarter of 2025, compared to 42.5% in the prior-year quarter, an increase of 1.2%. The year-over-year increase is primarily driven by lower production costs following the December 2024 closure of our Fremont, California manufacturing facility.

Total operating expenses in the third quarter of 2025 were $5.9 million, compared to $5.4 million in the third quarter of 2024. The increase is primarily attributable to an earnout write-down of $2.0 million that was recognized in the prior-year quarter. On a non-GAAP basis, which excludes the items listed in the attached non-GAAP reconciliation table, adjusted operating expenses were $5.7 million in the third quarter of 2025, compared to $6.7 million in the third quarter of 2024, a $1.0 million decrease. This decrease primarily reflects greater efficiency in reimbursement activities following receipt of the CMS code, improved productivity in marketing and sales operations, and lower R&D spending after the completion of major development programs. We expect this positive trend to continue in the fourth quarter of 2025 as these efficiency measures remain in place.

Operating loss in the third quarter of 2025 was $3.1 million, compared to $3.2 million in the third quarter of 2024. On a non-GAAP basis, which excludes the items in the attached non-GAAP reconciliation table, adjusted operating loss was $3.0 million in the third quarter of 2025, compared to a loss of $4.1 million in the third quarter of 2024.  

Net loss was $3.2 million, or $0.20 per share, for the third quarter of 2025, compared to a net loss of $3.1 million, or $0.35 per share, in the third quarter of 2024. On a non-GAAP basis, which excludes the items in the attached non-GAAP reconciliation table, adjusted net loss was $3.0 million, or $0.19 per share, in the third quarter of 2025, compared to $4.0 million, or $0.45 per share, during the third quarter of 2024.

Liquidity

As of September 30, 2025, Lifeward had $2.0 million in unrestricted cash and cash equivalents on its balance sheet with no debt. During the third quarter of 2025, cash used in operations was $3.8 million, compared to $4.5 million in the third quarter of 2024. The improvement primarily reflects operational efficiencies and the closure of the Fremont facility.

Following the end of the quarter, we entered into a $3.0 million loan agreement with Oramed Ltd., providing additional capital support to further strengthen our liquidity position.

2025 Financial Guidance

Lifeward is reaffirming its full-year 2025 guidance, including expected revenue in the range of $24 to $26 million and a projected non-GAAP net loss in the range of $12 to $14 million.

Conference Call

Lifeward management will host its conference call as follows:

Date		November 14, 2025
Time		8:30 AM EST
Telephone	U.S:	1-833-316-0561
	International:	1-412-317-0690
	Israel:	1-80-9212373
	Germany:	0800-6647650
Access code		Please reference the “Lifeward Earnings Call”
Webcast (live, listen-only and archive)		https://edge.media-server.com/mmc/p/522gfyx4

The archived webcast will be available via the following https://edge.media-server.com/mmc/p/522gfyx4 or through the “Investors” section on our website at GoLifeward.com.

About Lifeward

Lifeward designs, develops, and commercializes life-changing solutions that span the continuum of care in physical rehabilitation and recovery, delivering proven functional and health benefits in clinical settings as well as in the home and community. Our mission at Lifeward is to relentlessly drive innovation to change the lives of individuals with physical limitations or disabilities. We are committed to delivering groundbreaking solutions that empower individuals to do what they love. The Lifeward portfolio features innovative products including the ReWalk Exoskeleton, the AlterG Anti-Gravity system, the ReStore Exo-Suit, and the MyoCycle FES System.

Founded in 2001, Lifeward has operations in the United States, Israel, and Germany. For more information on the Lifeward mission and product portfolio, please visit GoLifeward.com.

Lifeward^®, ReWalk^®, ReStore^®, and Alter G^® are registered trademarks of Lifeward Ltd. and/or its affiliates.    

Forward-Looking Statements

In addition to historical information, this press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the U.S. Securities Act of 1933, and Section 21E of the U.S. Securities Exchange Act of 1934. Such forward-looking statements may include projections regarding the Company's future performance and other statements that are not statements of historical fact and, in some cases, may be identified by words like "anticipate," "assume," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "future," "will," "should," "would," "seek" and similar terms or phrases. The forward-looking statements contained in this press release are based on management's current expectations, which are subject to uncertainty, risks and changes in circumstances that are difficult to predict and many of which are outside of the Company’s control. Important factors that could cause the Company’s actual results to differ materially from those indicated in the forward-looking statements include, among others: the acceptance of the ReWalk 7 Personal Exoskeleton by healthcare professionals and patients; uncertainties associated with future clinical trials and the clinical development process, the product development process and FDA regulatory submission review and approval process; the Company's ability to have sufficient funds to meet certain future capital requirements, which could impair the Company's efforts to develop and commercialize existing and new products; the Company's ability to maintain and grow its reputation and the market acceptance of its products; the Company's ability to achieve reimbursement from third-party payors, including CMS, for its products; the Company's limited operating history and its ability to leverage its sales, marketing and training infrastructure; the Company's expectations as to its clinical research program and clinical results; the Company's expectations regarding future growth, including its ability to increase sales in its existing geographic markets and expand to new markets; the Company’s ability to continue to operate as a going concern; the Company's ability to obtain certain components of its products from third-party suppliers and its continued access to its product manufacturers; the Company’s ability to navigate any difficulties associated with moving production of its AlterG Anti-Gravity Systems to a contract manufacturer and transitioning the manufacturing of its ReWalk products to its in-house manufacturer; the Company's ability to improve its products and develop new products; the Company's compliance with medical device reporting regulations to report adverse events involving the Company's products, which could result in voluntary corrective actions or enforcement actions such as mandatory recalls, and the potential impact of such adverse events on the Company's ability to market and sell its products; the Company's ability to gain and maintain regulatory approvals; the Company's ability to maintain adequate protection of its intellectual property and to avoid violation of the intellectual property rights of others; the risk of a cybersecurity attack or breach of the Company's IT systems significantly disrupting its business operations; the Company's ability to use effectively the proceeds of its offerings of securities; and other factors discussed under the heading "Risk Factors" in the Company’s annual report on Form 10-K, as amended, for the year ended December 31, 2024 filed with the SEC and other documents subsequently filed with or furnished to the SEC. Any forward-looking statement made in this press release speaks only as of the date hereof. Factors or events that could cause the Company’s actual results to differ from the statements contained herein may emerge from time to time, and it is not possible for the Company to predict all of them. Except as required by law, the Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.

Non-GAAP Financial Measures

To supplement its consolidated financial statements, which are prepared and presented in accordance with U.S. Generally Accepted Accounting Principles (“GAAP”), the Company believes that the use of non-GAAP accounting measures, including non-GAAP net loss, is helpful to its investors. These measures, which the Company refers to as non-GAAP financial measures, are not prepared in accordance with GAAP.

Because of varying available valuation methodologies, subjective assumptions, and the variety of equity instruments that can impact a company’s non-cash expenses, the Company believes that providing non-GAAP financial measures that exclude non-cash share-based compensation expense and acquisition costs allows for more meaningful comparisons between operating results from period to period. Each of the Company’s non-GAAP financial measures is an important tool for financial and operational decision-making and for the Company’s evaluation of its operating results over different periods of time. The non-GAAP financial data are not measures of the Company’s financial performance under U.S. GAAP and should not be considered as alternatives to operating loss or net loss or any other performance measures derived in accordance with GAAP. Non-GAAP financial measures may not provide information that is directly comparable to that provided by other companies in Lifeward’s industry, as other companies in the industry may calculate non-GAAP financial results differently, particularly related to non-recurring, unusual items. In addition, there are limitations in using non-GAAP financial measures because the non-GAAP financial measures are not prepared in accordance with GAAP, may be different from non-GAAP financial measures used by other companies and exclude expenses that may have a material impact on the Company’s reported financial results. Further, share-based compensation expense has been, and will continue for the foreseeable future, to be a significant recurring expense in the Company’s business and an important part of the compensation provided to its employees.

The presentation of non-GAAP financial information is not meant to be considered in isolation or as a substitute for the directly comparable financial measures prepared in accordance with GAAP. Lifeward urges investors to review the reconciliation of the Company’s non-GAAP financial measures to the comparable GAAP financial measures included below, and not to rely on any single financial measure to evaluate the Company’s business.

Lifeward does not provide GAAP reconciliation of its non-GAAP financial guidance because the Company is unable to predict with reasonable certainty and without unreasonable effort items that would be included in such a reconciliation, including, but not limited to, stock-based compensation expense, acquisition-related expense, and earnout expense. The timing and amounts of these items are uncertain and could be material to Lifeward’s results computed in accordance with GAAP.

Lifeward Media Relations:
Almog Adar
Chief Financial Officer
Lifeward Ltd.
E: media@golifeward.com


Lifeward Investor Contact:
Almog Adar
Chief Financial Officer
Lifeward Ltd.
E: ir@golifeward.com

	Lifeward Ltd. And subsidiaries
	Condensed Consolidated Statements of Operations
	(Unaudited)
	(In thousands, except share and per share data)
			Three Months Ended								Nine Months Ended
			September 30,								September 30,
			2025				2024				2025				2024
	Revenue		$	6,195			$	6,128			$	16,953			$	18,118
	Cost of revenues			3,488				3,908				9,613				11,746
	Gross profit			2,707				2,220				7,340				6,372
	Operating expenses:
	Research and development, net			721				998				2,406				3,494
	Sales and marketing			3,168				4,156				10,790				13,573
	General and administrative			1,958				240				5,917				3,424
	Impairment charges			-				-				2,783				-
	Total operating expenses			5,847				5,394				21,896				20,491
	Operating loss			(3,140	)			(3,174	)			(14,556	)			(14,119	)
	Financial income (expenses), net			(23	)			119				8				495
	Loss before income taxes			(3,163	)			(3,055	)			(14,548	)			(13,624	)
	Taxes on income			7				29				18				40
	Net loss		$	(3,170	)		$	(3,084	)		$	(14,566	)		$	(13,664	)
	Basic net loss per ordinary share		$	(0.20	)		$	(0.35	)		$	(1.16	)		$	(1.58	)
	Weighted average number of shares used in computing net loss per ordinary share basic and diluted			16,021,411				8,756,882				12,603,487				8,652,085
	Lifeward Ltd. And subsidiaries
	Condensed Consolidated Balance Sheets
	(In thousands)
			(Unaudited)				(Audited)
			September 30,				December 31,
			2025				2024
	Assets
	Current assets
	Cash and cash equivalents		$	1,956			$	6,746
	Restricted Cash			234				197
	Trade receivables, net of credit losses of $193 and $160, respectively			6,126				6,004
	Prepaid expenses and other current assets			1,919				1,624
	Inventories			7,111				6,723
	Total current assets			17,346				21,294
	Restricted cash and other long term assets			205				240
	Operating lease right-of-use assets			221				548
	Property and equipment, net			641				867
	Goodwill			4,755				7,538
	Total assets		$	23,168			$	30,487
	Liabilities and equity
	Current liabilities
	Trade payables			5,251				5,022
	Current maturities of operating leases			149				858
	Other current liabilities			3,653				3,737
	Earnout liability			-				608
	Total current liabilities			9,053				10,225
	Non-current operating leases			88				22
	Other long-term liabilities			1,272				1,391
	Shareholders’ equity			12,755				18,849
	Total liabilities and equity		$	23,168			$	30,487
	Lifeward Ltd. And subsidiaries
	Condensed Consolidated Statements of Cash Flows
	(Unaudited)
	(In thousands)
			Nine Months Ended
			September 30,
			2025				2024
	Net cash used in operating activities		$	(13,271	)		$	(17,749	)
	Net cash used in investing activities			(5	)			-
	Net cash from financing activities			8,425				-
	Effect of Exchange rate changes on Cash, Cash Equivalents and Restricted Cash			103				(29	)
	Decrease in cash, cash equivalents, and restricted cash			(4,748	)			(17,778	)
	Cash, cash equivalents, and restricted cash at beginning of period			7,108				28,792
	Cash, cash equivalents, and restricted cash at end of period		$	2,360			$	11,014
	Lifeward Ltd. And subsidiaries
	(Unaudited)
	(In thousand)
			Three Months Ended								Nine Months Ended
			September 30,								September 30,
			2025				2024				2025				2024
	Revenues based on customer’s location:
	United States			4,044				3,458				10,263				11,054
	Germany			1,192				1,644				3,209				3,261
	Europe			627				775				2,100				2,635
	Asia - Pacific			103				150				269				544
	Rest of the world			229				101				1,112				624
	Total Revenues		$	6,195			$	6,128			$	16,953			$	18,118
			Three Months Ended																Nine Months Ended
			September 30,																September 30,
Dollars in thousands, except per share data			2025								2024								2025							2024
GAAP net loss			$	(3,170	)						$	(3,084	)						$	(14,566	)					$	(13,664	)
Adjustments:
	Amortization of intangible assets			-								842								-							2,505
	M&A transaction			-								-								-							(467	)
	Integration/Rebranding costs			-								-								-							236
	Restructuring			-								-								700							-
	Remeasurement of earnout liability			-								(2,008	)							(608	)						(2,500	)
	Impairment charges			-								-								2,783							-
	Stock-based compensation expenses			174								290								576							1,047
Non-GAAP net loss			$	(2,996	)						$	(3,960	)						$	(11,115	)					$	(12,843	)
Shares used in net loss per share				16,021,411								8,756,882								12,603,487							8,652,085
Non-GAAP net loss per share			$	(0.19	)						$	(0.45	)						$	(0.88	)					$	(1.48	)
			Three Months Ended																Nine Months Ended
			September 30,								September 30,								September 30,							September 30,
			2025								2024								2025							2024
Dollars in thousands			$				% of revenue				$				% of revenue				$				% of revenue			$				% of revenue
GAAP operating loss			$	(3,140	)			(50.7	)%		$	(3,174	)			(51.8	)%		$	(14,556	)		(85.9	)%		$	(14,119	)		(77.9	)%
	Amortization of intangible assets			-				-				842				13.7	%			-			-				2,505			13.8	%
	M&A transaction			-				-				-				-				-			-				(467	)		(2.6	)%
	Integration/Rebranding costs			-				-				-				-				-			-				236			1.3	%
	Restructuring			-				-				-				-				700			4.1	%			-			-
	Remeasurement of earnout liability			-				-				(2,008	)			(32.8	)%			(608	)		(3.6	)%			(2,500	)		(13.8	)%
	Impairment charges			-				-				-				-				2,783			16.4	%			-			-
	Stock-based compensation expenses			174				2.8	%			290				4.7	%			576			3.4	%			1,047			5.8	%
Non-GAAP operating loss			$	(2,966	)			(47.9	)%		$	(4,050	)			(66.2	)%		$	(11,105	)		(65.6	)%		$	(13,298	)		(73.4	)%
			Three Months Ended																Nine Months Ended
			September 30,								September 30,								September 30,							September 30,
			2025								2024								2025							2024
Dollars in thousands			$				% of revenue				$				% of revenue				$				% of revenue			$				% of revenue
GAAP gross profit			$	2,707				43.7	%		$	2,220				36.2	%		$	7,340			43.3	%		$	6,372			35.2	%
Adjustments:
	Amortization of intangible assets			-				-				387				6.3	%			-			-				1,153			6.4	%
	Stock-based compensation expenses			3				-				3				-				10			0.1	%			12			0.1	%
Non-GAAP gross profit			$	2,710				43.7	%		$	2,610				42.5	%		$	7,350			43.4	%		$	7,537			41.7	%
			Three Months Ended																Nine Months Ended
			September 30,								September 30,								September 30,							September 30,
			2025								2024								2025							2024
Dollars in thousands			$				% of revenue				$				% of revenue				$				% of revenue			$				% of revenue
GAAP research & development			$	721				11.6	%		$	998				16.3	%		$	2,406			14.2	%		$	3,494			19.3	%
Adjustments:
	Stock-based compensation expenses			(32	)			(0.5	)%			(38	)			(0.6	)%			(105	)		(0.6	)%			(130	)		(0.7	)%
Non-GAAP research & development			$	689				11.1	%		$	960				15.7	%		$	2,301			13.6	%		$	3,364			18.6	%
			Three Months Ended																Nine Months Ended
			September 30,								September 30,								September 30,							September 30,
			2025								2024								2025							2024
Dollars in thousands			$				% of revenue				$				% of revenue				$				% of revenue			$				% of revenue
GAAP sales & marketing			$	3,168				51.1	%		$	4,156				67.8	%		$	10,790			63.6	%		$	13,573			74.9	%
Adjustments:
	Amortization of intangible assets			-				-				(389	)			(6.3	)%			-			-				(1,154	)		(6.4	)%
	Integration/Rebranding costs			-				-				-				-				-			-				(193	)		(1.1	)%
	Restructuring			-				-				-				-				(277	)		(1.6	)%			-			-
	Stock-based compensation expenses			(65	)			(1.0	)%			(91	)			(1.5	)%			(203	)		(1.2	)%			(309	)		(1.7	)%
Non-GAAP sales & marketing			$	3,103				50.1	%		$	3,676				60.0	%		$	10,310			60.8	%		$	11,917			65.7	%
			Three Months Ended																Nine Months Ended
			September 30,								September 30,								September 30,							September 30,
			2025								2024								2025							2024
Dollars in thousands			$				% of revenue				$				% of revenue				$				% of revenue			$				% of revenue
GAAP general & administrative			$	1,958				31.6	%		$	240				3.9	%		$	5,917			34.9	%		$	3,424			18.9	%
Adjustments:
	M&A transaction			-				-				-				-				-			-				467			2.6	%
	Amortization of intangible assets			-				-				(66	)			(1.1	)%			-			-				(198	)		(1.1	)%
	Integration/Rebranding costs			-				-				-				-				-			-				(43	)		(0.2	)%
	Restructuring			-				-				-				-				(423	)		(2.5	)%			-			-
	Remeasurement of earnout liability			-				-				2,008				32.8	%			608			3.6	%			2,500			13.8	%
	Impairment			-				-				-				-				(2,783	)		(16.4	)%			-			-
	Stock-based compensation expenses			(74	)			(1.2	)%			(158	)			(2.6	)%			(258	)		(1.5	)%			(596	)		(3.3	)%
Non-GAAP general & administrative			$	1,884				30.4	%		$	2,024				33.0	%		$	3,061			18.1	%		$	5,554			30.7	%

FAQ

What were Lifeward (LFWD) Q3 2025 revenue and net loss reported on Nov 14, 2025?

Lifeward reported Q3 2025 revenue $6.2M and a net loss $3.2M ($0.20 per share).

How did Lifeward's cash burn change in Q3 2025 and what was cash used in operations?

Quarterly cash used in operations improved to $3.8M, a 16% reduction YoY from Q3 2024.

What does Lifeward's CE mark for ReWalk 7 mean for LFWD shareholders?

CE mark approval permits commercial sales in Europe, which represents about 40% of the company’s exoskeleton sales.

How does the $3.0M loan from Oramed affect Lifeward's liquidity for investors?

The $3.0M loan was entered after quarter‑end to provide additional capital support and strengthen liquidity.

Did Lifeward change its 2025 guidance after Q3 2025 results?

No; Lifeward reaffirmed full‑year 2025 guidance of $24–$26M revenue and a $12–$14M non‑GAAP net loss.

Why did Lifeward's adjusted gross margin improve in Q3 2025?

Adjusted gross margin rose to 43.7%, driven primarily by lower production costs after the December 2024 Fremont facility closure.